Explanipedia

Environmental risk factors of inflammatory bowel disease: toward a strategy of preventative health Open

Tarun Chhibba, Beatriz Gros, James A. King, Joseph W. Windsor, Julia Gorospe , et al. · 2025

The pathogenesis of inflammatory bowel disease (IBD) involves a complex interplay between genetic, environmental, and microbial factors. Many of these environmental determinants are modifiable, offering opportunities to prevent disease or …

Data Visualization in the Era of COVID-19: An Interactive Map of the SECURE-IBD Registry. Open

Joseph W. Windsor, Fox E. Underwood, Erica J. Brenner, Jean‐Frédéric Colombel, Michael D. Kappelman , et al. · 2024

Many patients with inflammatory bowel disease (IBD) are immunocompromised, making them potentially more susceptible to severe complications of coronavirus disease of 2019 (COVID 19) including hospitalization, intensive care unit admission,…

Forecasting the Incidence and Prevalence of Inflammatory Bowel Disease: A Canadian Nationwide Analysis Open

Stephanie Coward, Eric I. Benchimol, Çharles N. Bernstein, Antonio Aviña-Zubieta, Alain Bitton , et al. · 2024

INTRODUCTION: Canada has a high burden of inflammatory bowel disease (IBD). Historical trends of IBD incidence and prevalence were analyzed to forecast the Canadian burden over the next decade. METHODS: Population-based surveillance cohort…

THE COST OF INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED ANALYSIS OF ADMINISTRATIVE DATA Open

Stephanie Coward, Joseph W. Windsor, Eric I. Benchimol, Çharles N. Bernstein, Antonio Aviña-Zubieta , et al. · 2024

BACKGROUND As the global prevalence of inflammatory bowel disease (IBD) rises, it is important that the direst costs associated with medical care be analyzed to determine the impact on healthcare systems. Components making up the direct he…

EPIDEMIOLOGY OF INFLAMMATORY BOWEL DISEASE AMONG EARLY-INDUSTRIALIZED REGIONS OF THE WORLD: CHALLENGES IN SUSTAINABLE HEALTHCARE DELIVERY Open

Michelle Herauf, Stephanie Coward, Juan Nicolás Peña-Sánchez, Çharles N. Bernstein, Eric I. Benchimol , et al. · 2024

BACKGROUND Early-industrialized regions (e.g., North America, Europe, Oceania) are currently in stage 3 of the epidemiologic evolution of inflammatory bowel disease (IBD), compounding prevalence wherein incidence stabilizes, but prevalence…

TRENDS IN INFLAMMATORY BOWEL DISEASE INCIDENCE AND PREVALENCE ACROSS EPIDEMIOLOGIC STAGES: A GLOBAL SYSTEMATIC REVIEW WITH META-ANALYSIS Open

Julia Gorospe, Joseph W. Windsor, Lindsay Hracs, Stephanie Coward, Michael Buie , et al. · 2024

BACKGROUND Rising incidence and prevalence of inflammatory bowel disease (IBD) observed historically in early-industrialized regions now also appear in newly-industrialized and emerging regions. The epidemiology of IBD has been proposed to…

EXPLORING FACTORS ASSOCIATED WITH SEROLOGICAL RESPONSE TO SARS-COV-2 VACCINES IN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE: INTERACTIVE VISUALIZATION METHODS FOR MULTIDIMENSIONAL DATA Open

Lindsay Hracs, Joshua Quan, Christopher Ma, Remo Panaccione, Nastaran Sharifi , et al. · 2024

BACKGROUND SARS-CoV-2 vaccine response may be reduced in seniors (age 65+) with inflammatory bowel disease (IBD) and those on anti-TNF therapy. A challenge of the COVID-19 era has been conveying rapid-evolving health information, especiall…

MODELING THE TRANSITION TO THE FOURTH EPIDEMIOLOGIC STAGE OF INFLAMMATORY BOWEL DISEASE: PREVALENCE EQUILIBRIUM Open

Joseph W. Windsor, Lindsay Hracs, K. Michael Cummings, Julia Gorospe, Michael Buie , et al. · 2024

BACKGROUND A theoretical framework for population-level transition across four epidemiologic stages has been proposed for inflammatory bowel disease (IBD): 1. Emergence (low incidence/prevalence); 2. Acceleration in Incidence (rapid rising…

MACHINE LEARNING CLASSIFICATION OF THE EPIDEMIOLOGIC STAGES OF INFLAMMATORY BOWEL DISEASE ACROSS GEOGRAPHY AND TIME Open

Lindsay Hracs, Joseph W. Windsor, Julia Gorospe, Michael Buie, Joshua Quan , et al. · 2024

BACKGROUND Epidemiologic stages of inflammatory bowel disease (IBD) have been proposed: 1. Emergence (low incidence and prevalence); 2. Acceleration in Incidence (rapidly rising incidence, low prevalence); and 3. Compounding Prevalence (st…

The Global Evolution of Inflammatory Bowel Disease across Four Epidemiologic Stages Open

Gilaad G. Kaplan, Lindsay Hracs, Joseph W. Windsor, Julia Gorospe, K. Michael Cummings , et al. · 2024

During the 20th century, inflammatory bowel disease (IBD) was considered a disease of early-industrialized regions in North America, Europe, and Oceania. At the turn of the 21st century, incidence of IBD increased in newly-industrialized a…

The 2023 Impact of Inflammatory Bowel Disease in Canada: Direct Health System and Medication Costs Open

M Ellen Kuenzig, Stephanie Coward, Laura E. Targownik, Sanjay K. Murthy, Eric I. Benchimol , et al. · 2023

Healthcare utilization among people living with inflammatory bowel disease (IBD) in Canada has shifted from inpatient management to outpatient management; fewer people with IBD are admitted to hospitals or undergo surgery, but outpatient v…

The 2023 Impact of Inflammatory Bowel Disease in Canada: Indirect (Individual and Societal) and Direct Out-of-Pocket Costs Open

M Ellen Kuenzig, James Im, Stephanie Coward, Joseph W. Windsor, Gilaad G. Kaplan , et al. · 2023

People living with inflammatory bowel disease (IBD) and their caregivers are faced with indirect and out-of-pocket costs that they would not otherwise experience. These costs impact one’s ability to contribute to the economy to their fulle…

The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations—Children and Adolescents with IBD Open

Wael El‐Matary, Matthew Carroll, Colette Deslandres, Anne M. Griffiths, M Ellen Kuenzig , et al. · 2023

Rates of inflammatory bowel disease (IBD) in Canadian children and adolescents are among the highest in the world, and the incidence is rising most rapidly in children under five years of age. These young children may have either a typical…

The 2023 Impact of Inflammatory Bowel Disease in Canada: Treatment Landscape Open

Sanjay K. Murthy, Adam V. Weizman, M Ellen Kuenzig, Joseph W. Windsor, Gilaad G. Kaplan , et al. · 2023

The therapeutic landscape for inflammatory bowel disease (IBD) has changed considerably over the past two decades, owing to the development and widespread penetration of targeted therapies, including biologics and small molecules. While so…

The 2023 Impact of Inflammatory Bowel Disease in Canada: COVID-19 and IBD Open

Gilaad G. Kaplan, M Ellen Kuenzig, Joseph W. Windsor, Çharles N. Bernstein, Alain Bitton , et al. · 2023

The COVID-19 pandemic had a monumental impact on the inflammatory bowel disease (IBD) community. At the beginning of the pandemic, knowledge on the effect of SARS-CoV-2 on IBD was lacking, especially in those with medication-suppressed imm…

The 2023 Impact of Inflammatory Bowel Disease in Canada: The Influence of Sex and Gender on Canadians Living With Inflammatory Bowel Disease Open

Laura E Targownik, Natasha Bollegala, Vivian Huang, Joseph W. Windsor, M Ellen Kuenzig , et al. · 2023

Sex (the physical and physiologic effects resulting from having specific combinations of sex chromosomes) and gender (sex-associated behaviours, expectations, identities, and roles) significantly affect the course of inflammatory bowel dis…

The 2023 Impact of Inflammatory Bowel Disease in Canada: Cancer and IBD Open

Sanjay K. Murthy, M Ellen Kuenzig, Joseph W. Windsor, Priscilla Matthews, Parul Tandon , et al. · 2023

Cancer is a major cause of morbidity and mortality among people with inflammatory bowel disease (IBD). Intestinal cancers may arise as a complication of IBD itself, while extra-intestinal cancers may arise due to some of the immunosuppress…

The 2023 Impact of Inflammatory Bowel Disease in Canada: Epidemiology of IBD Open

Stephanie Coward, Eric I. Benchimol, M Ellen Kuenzig, Joseph W. Windsor, Çharles N. Bernstein , et al. · 2023

Inflammatory bowel disease (IBD), consisting of Crohn’s disease and ulcerative colitis, is recognized across the world, though Canada has among the highest burdens of IBD in the world. The Canadian Gastro-Intestinal Epidemiology Consortium…

The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations—IBD in Seniors Open

Seth R. Shaffer, M Ellen Kuenzig, Joseph W. Windsor, Alain Bitton, Jennifer Jones , et al. · 2023

Approximately one out of every 88 seniors has inflammatory bowel disease (IBD), and this is expected to increase in the future. They are more likely to have left-sided disease in ulcerative colitis, and isolated colonic disease in Crohn’s …

The 2023 Impact of Inflammatory Bowel Disease in Canada: Mental Health and Inflammatory Bowel Disease Open

Lesley A. Graff, Rose Geist, M Ellen Kuenzig, Eric I. Benchimol, Gilaad G. Kaplan , et al. · 2023

Psychiatric disorders are 1.5 to 2 times more prevalent in persons with inflammatory bowel disease (IBD) than in the general population, with pooled prevalence estimates of 21% for clinical anxiety and 15% for depression. Rates are even hi…

The 2023 Impact of Inflammatory Bowel Disease in Canada: Access to and Models of Care Open

Holly Mathias, Noelle Rohatinsky, Sanjay K. Murthy, Kerri L. Novak, M Ellen Kuenzig , et al. · 2023

Rising compounding prevalence of inflammatory bowel disease (IBD) (Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18:56–66.) and pandemic-ex…

The 2023 Impact of Inflammatory Bowel Disease in Canada: Executive Summary Open

Joseph W. Windsor, M Ellen Kuenzig, Sanjay K. Murthy, Alain Bitton, Çharles N. Bernstein , et al. · 2023

The burden of inflammatory bowel disease (IBD) (i.e., associated direct and indirect costs, prevalence of disease, personal impact to the individual and to caregivers) continues to increase in Canada. The prevalence of IBD has increased si…

Adverse Events and Serological Responses After SARS-CoV-2 Vaccination in Individuals With Inflammatory Bowel Disease Open

Ante Markovinović, Joshua Quan, Michelle Herauf, Lindsay Hracs, Joseph W. Windsor , et al. · 2023

INTRODUCTION: We determined adverse events after 4 doses of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine in those with inflammatory bowel disease (IBD), associations between antibodies and injection site reactions (…

A210 THE BURDEN OF IBD HOSPITALIZATION IN CANADA: AN ASSESSMENT OF THE CURRENT AND FUTURE BURDEN IN A NATION-WIDE ANALYSIS Open

Stephanie Coward, Eric I. Benchimol, C N Bernstein, J. Antonio Aviña‐Zubieta, Alain Bitton , et al. · 2023

Background Hospitalizations pose a significant burden on both the individual and the healthcare system. Those with inflammatory bowel disease (IBD) are at increased risk of hospitalization as compared to the general population due to flari…

A35 FORECASTING THE INCIDENCE AND PREVALENCE OF INFLAMMATORY BOWEL DISEASE: A CANADIAN NATION-WIDE ANALYSIS Open

Stephanie Coward, Eric I. Benchimol, Çharles N. Bernstein, J. Antonio Aviña‐Zubieta, Alain Bitton , et al. · 2023

Background Canada is currently in the third epidemiological stage in the evolution of IBD: compounding prevalence. A high incidence of IBD, in conjunction with low mortality, leads to a steadily rising prevalence over time. By understandin…

A170 ADVERSE EVENTS & SEROLOGICAL RESPONSES FOLLOWING SARS-COV-2 VACCINATION IN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE Open

Ante Markovinović, Michelle Herauf, Joshua Quan, Lindsay Hracs, Joseph W. Windsor , et al. · 2023

Background The rapid development and distribution of SARS-CoV-2 vaccines has raised concerns surrounding vaccine safety in immunocompromised populations, such as those with inflammatory bowel disease (IBD). Purpose We described adverse eve…

A193 DEMOGRAPHIC, SOCIAL AND OCCUPATIONAL FACTORS THAT PREVENTED EXPOSURE TO SARS-COV-2 IN INFLAMMATORY BOWEL DISEASE PATIENTS DURING THE COVID-19 PANDEMIC: A PROSPECTIVE COHORT STUDY Open

Léa Caplan, Nasrin Sharifi, Ante Markovinović, Michelle Herauf, Joshua Quan , et al. · 2023

Background The COVID-19 pandemic caused by the SARS-CoV-2 virus is a rapidly evolving public health emergency in which mundane behaviors such as grocery shopping or restaurant dining are considered high-risk for some, such as persons with …

A188 INFORMING IMMUNOCOMPROMISED POPULATIONS: AN EFFECTIVE AND EFFICIENT COVID-19 KNOWLEDGE TRANSLATION STRATEGY Open

Joseph W. Windsor, Stephanie Coward, K Lee, A Specic, S Ghandeharian , et al. · 2023

Background Throughout the COVID-19 pandemic, one of the major challenges was conveying expert health information, which was evolving rapidly, to confer population-level advice; this was especially relevant to at risk groups, such as those …

A195 DURABILITY OF SEROLOGICAL RESPONSES AFTER SECOND, THIRD AND FOURTH DOSE OF SARS-COV-2 VACCINATION IN INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE COHORT STUDY Open

Nasrin Sharifi, Christopher Ma, Cynthia H. Seow, Joshua Quan, Lindsay Hracs , et al. · 2023

Background Adequate serological responses following two-dose regimens and additional doses of SARS-CoV-2 vaccination have been demonstrated for the vast majority of those with IBD. However, antibody levels following 2nd, 3rd, and 4th dose …

A169 THE DIRECT COSTS OF INFLAMMATORY BOWEL DISEASE IN CANADA: A POPULATION-BASED ANALYSIS OF HISTORICAL AND CURRENT COSTS Open

Stephanie Coward, Eric I. Benchimol, C N Bernstein, J. Antonio Aviña‐Zubieta, Alain Bitton , et al. · 2023

Background Inflammatory bowel disease (IBD) is a costly disease to manage due to hospitalizations, regular ambulatory monitoring, and expensive pharmaceutical therapies. While hospitalization rates have fallen, the increased use of biologi…

Joseph W. Windsor YOU? Author Swipe